BRIEF-Capricor Therapeutics Provides Regulatory Update On Deramiocel BLA For Duchenne Muscular Dystrophy

Reuters

Jul 11

BRIEF-Capricor <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Provides Regulatory Update On Deramiocel BLA For Duchenne Muscular Dystrophy

July 11 (Reuters) - Capricor Therapeutics Inc CAPR.O:

CAPRICOR THERAPEUTICS PROVIDES REGULATORY UPDATE ON DERAMIOCEL BLA FOR DUCHENNE MUSCULAR DYSTROPHY
CAPRICOR THERAPEUTICS INC - FDA ISSUES COMPLETE RESPONSE LETTER TO CAPRICOR
CAPRICOR THERAPEUTICS INC - TO RESUBMIT BLA WITH PHASE 3 DATA IN Q3 2025
CAPRICOR THERAPEUTICS INC - FDA ADVISES CAPRICOR TO REQUEST MEETING FOR APPROVAL
CAPRICOR THERAPEUTICS: FDA SAID DERAMIOCEL BLA DOES NOT MEET STATUTORY REQUIREMENT FOR SUBSTANTIAL EVIDENCE OF EFFECTIVENESS

Source text: ID:nGNX4r3vQz

Further company coverage: CAPR.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2550324569"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2550324569\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2550324569?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-11 18:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2550324569","market":"us","top_or_hot":-1,"title":"BRIEF-Capricor Therapeutics Provides Regulatory Update On Deramiocel BLA For Duchenne Muscular Dystrophy","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Capricor <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Provides Regulatory Update On Deramiocel BLA For Duchenne Muscular Dystrophy</title></head><body><p><span>July 11 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/CAPR\">Capricor Therapeutics Inc</a> <span>CAPR.O</span>:</p><ul><li><p>CAPRICOR THERAPEUTICS PROVIDES REGULATORY UPDATE ON DERAMIOCEL BLA FOR DUCHENNE MUSCULAR DYSTROPHY</p></li><li><p>CAPRICOR THERAPEUTICS INC - FDA ISSUES COMPLETE RESPONSE LETTER TO CAPRICOR</p></li><li><p>CAPRICOR THERAPEUTICS INC - TO RESUBMIT BLA WITH PHASE 3 DATA IN Q3 2025</p></li><li><p>CAPRICOR THERAPEUTICS INC - FDA ADVISES CAPRICOR TO REQUEST MEETING FOR APPROVAL</p></li><li><p>CAPRICOR THERAPEUTICS: FDA SAID DERAMIOCEL BLA DOES NOT MEET STATUTORY REQUIREMENT FOR SUBSTANTIAL EVIDENCE OF EFFECTIVENESS</p></li></ul><p>Source text: <span>ID:nGNX4r3vQz</span></p><p>Further company coverage: <span>CAPR.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Capricor Therapeutics Provides Regulatory Update On Deramiocel BLA For Duchenne Muscular Dystrophy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Capricor Therapeutics Provides Regulatory Update On Deramiocel BLA For Duchenne Muscular Dystrophy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-11 18:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Capricor <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Provides Regulatory Update On Deramiocel BLA For Duchenne Muscular Dystrophy</title></head><body><p><span>July 11 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/CAPR\">Capricor Therapeutics Inc</a> <span>CAPR.O</span>:</p><ul><li><p>CAPRICOR THERAPEUTICS PROVIDES REGULATORY UPDATE ON DERAMIOCEL BLA FOR DUCHENNE MUSCULAR DYSTROPHY</p></li><li><p>CAPRICOR THERAPEUTICS INC - FDA ISSUES COMPLETE RESPONSE LETTER TO CAPRICOR</p></li><li><p>CAPRICOR THERAPEUTICS INC - TO RESUBMIT BLA WITH PHASE 3 DATA IN Q3 2025</p></li><li><p>CAPRICOR THERAPEUTICS INC - FDA ADVISES CAPRICOR TO REQUEST MEETING FOR APPROVAL</p></li><li><p>CAPRICOR THERAPEUTICS: FDA SAID DERAMIOCEL BLA DOES NOT MEET STATUTORY REQUIREMENT FOR SUBSTANTIAL EVIDENCE OF EFFECTIVENESS</p></li></ul><p>Source text: <span>ID:nGNX4r3vQz</span></p><p>Further company coverage: <span>CAPR.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CAPR","symbol_name":"Capricor Therapeutics Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250711:nTUAC8KHLY:1","article_id":"2550324569","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2550324569","pubTimestamp":1752229950,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Capricor Therapeutics Provides Regulatory Update On Deramiocel BLA For Duchenne Muscular DystrophyJuly 11 (Reuters) - Capricor Therapeutics Inc CAPR.O:CAPRICOR THERAPEUTICS PROVIDES REGULATORY U","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CAPR":"Capricor Therapeutics Inc","BK4139":"生物科技"},"translate_title":"简介-Capricor Therapeutics提供Deramiocel BLA治疗杜氏肌营养不良症的监管更新","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CAPR":0.9},"content_text":"BRIEF-Capricor Therapeutics Provides Regulatory Update On Deramiocel BLA For Duchenne Muscular DystrophyJuly 11 (Reuters) - Capricor Therapeutics Inc CAPR.O:CAPRICOR THERAPEUTICS PROVIDES REGULATORY UPDATE ON DERAMIOCEL BLA FOR DUCHENNE MUSCULAR DYSTROPHYCAPRICOR THERAPEUTICS INC - FDA ISSUES COMPLETE RESPONSE LETTER TO CAPRICORCAPRICOR THERAPEUTICS INC - TO RESUBMIT BLA WITH PHASE 3 DATA IN Q3 2025CAPRICOR THERAPEUTICS INC - FDA ADVISES CAPRICOR TO REQUEST MEETING FOR APPROVALCAPRICOR THERAPEUTICS: FDA SAID DERAMIOCEL BLA DOES NOT MEET STATUTORY REQUIREMENT FOR SUBSTANTIAL EVIDENCE OF EFFECTIVENESSSource text: ID:nGNX4r3vQzFurther company coverage: CAPR.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}